Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Edetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.48 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.46 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.46 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.46 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.46 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | EYA2 | O00167 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL1714086 | 1.00 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL10607814 | 1.00 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL8374505 | 1.00 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL978169 | 1.00 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL7071979 | 1.00 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL506851 | 1.00 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL8470881 | 1.00 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL5273812 | 0.97 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL3394139 | 0.97 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL17747958 | 0.97 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118948757-A | Sodium hyaluronate eye drops and preparation method thereof | 博济医药科技股份有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-111295202-B | External preparation for treating onychomycosis | 科研制药株式会社 | 2022-07-08 | — | — | CN | claimed |
| WO-2021112240-A1 | RHINENCHYSIS COMPOSITION CONTAINING OLOPATADINE | 東興薬品工業株式会社 | 2021-06-10 | — | — | WO | claimed |
| WO-2021112242-A1 | PHARMACEUTICAL COMPOSITION COMPRISING STEROID COMPOUND AND OLOPATADINE | 東興薬品工業株式会社 | 2021-06-10 | — | — | WO | claimed |
| CN-112566635-A | Granular composition and process for producing the same | 日本脏器制药株式会社 | 2021-03-26 | — | — | CN | claimed |
| CN-111836627-A | Composition for suppressing pollen cracking | 参天制药株式会社 | 2020-10-27 | — | — | CN | claimed |
| CN-111712238-A | Eye drops containing 2-amino-3- (4-bromobenzoyl) phenylacetic acid or its salt | 参天制药株式会社 | 2020-09-25 | — | — | CN | claimed |
| CN-111295202-A | External preparation for treating onychomycosis | 科研制药株式会社 | 2020-06-16 | — | — | CN | claimed |
| WO-2020032159-A1 | PARTICULATE COMPOSITION AND PRODUCTION METHOD THEREFOR | 日本臓器製薬株式会社 | 2020-02-13 | — | — | WO | claimed |
| WO-2019176947-A1 | POLLEN BURSTING-INHIBITING COMPOSITION | 参天製薬株式会社 | 2019-09-19 | — | — | WO | claimed |
| WO-2012169849-A2 | EYE-DROP COMPOSITION FOR PREVENTING OR TREATING OCULAR DISEASES | HUONS CO., LTD. (KR) | 2012-12-13 | — | — | WO | claimed |
| US-5449658-A | Biocidal compositions comprising polyhexamethylene biguanide and EDTA, and methods for treating commercial and recreational water | ZENECA, INC. (US) | 1995-09-12 | — | — | US | claimed |
| WO-1995015683-A1 | BIOCIDAL COMPOSITIONS AND METHODS FOR TREATING COMMERCIAL AND RECREATIONAL WATER | ZENECA, INC. (US) | 1995-06-15 | — | — | WO | claimed |
| US-20260116959-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-PD-L1 ANTIBODY USED IN COMBINATION WITH ANTI-VEGF ANTIBODY AND PACLITAXEL (as amended) | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20260098160-A1 | WATER RESISTANCE FOR ORGANIC FACADES | ROHM & HAAS (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260008775-A1 | AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | CONVELO THERAPEUTICS, INC. | 2026-01-08 | — | — | US | disclosed |
| EP-0702662-A1 | METHOD FOR TREATING WATER USING AN ORGANIC SANITIZER AND A PERSULFATE | FMC CORPORATION (US) | 1996-03-27 | — | — | EP | disclosed |
| US-5501802-A | SWIMMING POOL | FMC CORPORATION (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1995015683-A1 | BIOCIDAL COMPOSITIONS AND METHODS FOR TREATING COMMERCIAL AND RECREATIONAL WATER | ZENECA, INC. (US) | 1995-06-15 | — | — | WO | disclosed |
| WO-1994024054-A1 | METHOD FOR TREATING WATER USING AN ORGANIC SANITIZER AND A PERSULFATE | FMC CORPORATION (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098160-A1 | WATER RESISTANCE FOR ORGANIC FACADES | ERG, LATS2, FTO | ACE 3061/4885CHRM2 2644/4885ADRA2A 1814/4885 |
| US-20260116959-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-PD-L1 ANTIBODY USED IN COMBINATION WITH ANTI-VEGF ANTIBODY AND PACLITAXEL (as amended) | PDCD1LG2, CD274, PDCD1 | ACE 3251/4885CHRM2 2403/4885ADRA2A 1008/4885 |
| US-20260008775-A1 | AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H3, NR1H2 | ACE 4489/4885CHRM2 278/4885ADRA2A 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.